171 related articles for article (PubMed ID: 17197429)
21. Specific iron chelators determine the route of ferritin degradation.
De Domenico I; Ward DM; Kaplan J
Blood; 2009 Nov; 114(20):4546-51. PubMed ID: 19671920
[TBL] [Abstract][Full Text] [Related]
22. Effect of iron deficiency on c-kit⁺ cardiac stem cells in vitro.
Song D; Li Y; Cao J; Han Z; Gao L; Xu Z; Yin Z; Wang G; Fan Y; Wang C
PLoS One; 2013; 8(6):e65721. PubMed ID: 23762416
[TBL] [Abstract][Full Text] [Related]
23. Beta2-adrenergic receptor agonists and cAMP arrest human cultured airway smooth muscle cells in the G(1) phase of the cell cycle: role of proteasome degradation of cyclin D1.
Stewart AG; Harris T; Fernandes DJ; Schachte LC; Koutsoubos V; Guida E; Ravenhall CE; Vadiveloo P; Wilson JW
Mol Pharmacol; 1999 Nov; 56(5):1079-86. PubMed ID: 10531416
[TBL] [Abstract][Full Text] [Related]
24. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine.
Gharagozloo M; Khoshdel Z; Amirghofran Z
Eur J Pharmacol; 2008 Jul; 589(1-3):1-7. PubMed ID: 18619590
[TBL] [Abstract][Full Text] [Related]
25. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
Richardson D; Ponka P; Baker E
Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
[TBL] [Abstract][Full Text] [Related]
27. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
28. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
29. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation.
Okabe H; Lee SH; Phuchareon J; Albertson DG; McCormick F; Tetsu O
PLoS One; 2006 Dec; 1(1):e128. PubMed ID: 17205132
[TBL] [Abstract][Full Text] [Related]
30. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
Richardson DR; Ponka P
J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
[TBL] [Abstract][Full Text] [Related]
31. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
[TBL] [Abstract][Full Text] [Related]
32. Enhanced neurogenesis from neural progenitor cells with G1/S-phase cell cycle arrest is mediated by transforming growth factor beta1.
Misumi S; Kim TS; Jung CG; Masuda T; Urakawa S; Isobe Y; Furuyama F; Nishino H; Hida H
Eur J Neurosci; 2008 Sep; 28(6):1049-59. PubMed ID: 18783370
[TBL] [Abstract][Full Text] [Related]
33. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F
Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396
[TBL] [Abstract][Full Text] [Related]
34. Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells.
Zhang Q; Tian L; Mansouri A; Korapati AL; Johnson TJ; Claret FX
FEBS Lett; 2005 Jul; 579(18):3932-40. PubMed ID: 15996662
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
Green DA; Antholine WE; Wong SJ; Richardson DR; Chitambar CR
Clin Cancer Res; 2001 Nov; 7(11):3574-9. PubMed ID: 11705879
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
Alao JP; Stavropoulou AV; Lam EW; Coombes RC; Vigushin DM
Mol Cancer; 2006 Feb; 5():8. PubMed ID: 16504004
[TBL] [Abstract][Full Text] [Related]
38. Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells.
Qin C; Burghardt R; Smith R; Wormke M; Stewart J; Safe S
Cancer Res; 2003 Mar; 63(5):958-64. PubMed ID: 12615709
[TBL] [Abstract][Full Text] [Related]
39. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells.
Masamha CP; Benbrook DM
Cancer Res; 2009 Aug; 69(16):6565-72. PubMed ID: 19638577
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of cell cycle regulation by FIP200 in human breast cancer cells.
Melkoumian ZK; Peng X; Gan B; Wu X; Guan JL
Cancer Res; 2005 Aug; 65(15):6676-84. PubMed ID: 16061648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
